These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 36066961)

  • 1. Microdosing psilocybin for chronic pain: a case series.
    Lyes M; Yang KH; Castellanos J; Furnish T
    Pain; 2023 Apr; 164(4):698-702. PubMed ID: 36066961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compassionate use of psychedelics.
    Greif A; Šurkala M
    Med Health Care Philos; 2020 Sep; 23(3):485-496. PubMed ID: 32468195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adapting psychedelic medicine for headache and chronic pain disorders.
    Schindler EAD; Hendricks PS
    Expert Rev Neurother; 2023; 23(10):867-882. PubMed ID: 37652000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are psychedelics the answer to chronic pain: A review of current literature.
    Kooijman NI; Willegers T; Reuser A; Mulleners WM; Kramers C; Vissers KCP; van der Wal SEI
    Pain Pract; 2023 Apr; 23(4):447-458. PubMed ID: 36597700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beating pain with psychedelics: Matter over mind?
    Elman I; Pustilnik A; Borsook D
    Neurosci Biobehav Rev; 2022 Mar; 134():104482. PubMed ID: 34922987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychedelics as preventive treatment in headache and chronic pain disorders.
    Schindler EAD
    Neuropharmacology; 2022 Sep; 215():109166. PubMed ID: 35718005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing potential of psilocybin for depressive disorders.
    Kozak Z; Johnson MW; Aaronson ST
    Expert Opin Investig Drugs; 2023; 32(10):887-900. PubMed ID: 37869790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
    Carhart-Harris RL; Bolstridge M; Rucker J; Day CM; Erritzoe D; Kaelen M; Bloomfield M; Rickard JA; Forbes B; Feilding A; Taylor D; Pilling S; Curran VH; Nutt DJ
    Lancet Psychiatry; 2016 Jul; 3(7):619-27. PubMed ID: 27210031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychedelic microdosing benefits and challenges: an empirical codebook.
    Anderson T; Petranker R; Christopher A; Rosenbaum D; Weissman C; Dinh-Williams LA; Hui K; Hapke E
    Harm Reduct J; 2019 Jul; 16(1):43. PubMed ID: 31288862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study.
    Cavarra M; Mason NL; Kuypers KPC; Bonnelle V; Smith WJ; Feilding A; Kryskow P; Ramaekers JG
    Eur J Pain; 2024 Jan; 28(1):153-165. PubMed ID: 37599279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat.
    Smigielski L; Kometer M; Scheidegger M; Krähenmann R; Huber T; Vollenweider FX
    Sci Rep; 2019 Oct; 9(1):14914. PubMed ID: 31649304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
    Lea T; Amada N; Jungaberle H; Schecke H; Klein M
    Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms.
    Skosnik PD; Sloshower J; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC
    J Psychopharmacol; 2023 Jul; 37(7):687-697. PubMed ID: 37392016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Psilocybin's Adverse Effects Mostly Resolved Within 2 Days.
    Harris E
    JAMA; 2024 May; 331(20):1699. PubMed ID: 38700847
    [No Abstract]   [Full Text] [Related]  

  • 15. Dosing Psychedelics and MDMA.
    Liechti ME; Holze F
    Curr Top Behav Neurosci; 2022; 56():3-21. PubMed ID: 34734392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychedelics and Psychedelic-Assisted Psychotherapy.
    Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
    Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microdosing psychedelics: More questions than answers? An overview and suggestions for future research.
    Kuypers KP; Ng L; Erritzoe D; Knudsen GM; Nichols CD; Nichols DE; Pani L; Soula A; Nutt D
    J Psychopharmacol; 2019 Sep; 33(9):1039-1057. PubMed ID: 31303095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs.
    Zia FZ; Baumann MH; Belouin SJ; Dworkin RH; Ghauri MH; Hendricks PS; Henningfield JE; Lanier RK; Ross S; Berger A
    Neuropharmacology; 2023 Aug; 233():109528. PubMed ID: 37015315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats.
    Kiilerich KF; Lorenz J; Scharff MB; Speth N; Brandt TG; Czurylo J; Xiong M; Jessen NS; Casado-Sainz A; Shalgunov V; Kjaerby C; Satała G; Bojarski AJ; Jensen AA; Herth MM; Cumming P; Overgaard A; Palner M
    Mol Psychiatry; 2023 Sep; 28(9):3829-3841. PubMed ID: 37783788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.